Search

Your search keyword '"Vu, Hoan"' showing total 141 results
Start Over Author "Vu, Hoan"
141 results on '"Vu, Hoan"'

1. Tunable Plasmonic Nanoantennas in Rolled-up Microtubes Coupled to Integrated Quantum Wells

Author

Vu, Hoan, Siebels, Jan, Sonnenberg, David, Mendach, Stefan, and Kipp, Tobias

Subjects
Physics - Optics
Abstract

We propose and realize a tunable plasmonic nanoantenna design consisting of two stacked Ag cuboids that are integrated into a rolled-up semiconductor microtube. The antenna's resonance is tuned by varying the cuboid's distance to match the photoluminescence emission of an embedded GaAs quantum well. Spatially, spectrally and temporally resolved photoluminescence measurements reveal a redshift and a reduction in lifetime of the quantum-well emission as signatures for the coupling to the antenna system. By means of finite-element electromagnetic simulations, we assign the coupling to an excitation of a high-order plasmonic mode inside the Ag cuboids., Comment: This document is the unedited Author's version of a Submitted Work that was subsequently accepted for publication in ACS Photonics, copyright American Chemical Society after peer review. To access the final edited and published work see http://pubs.acs.org/articlesonrequest/AOR-SSNAn2JmMfr3KzD5ii2R

Published
2017
Full Text
View/download PDF

8. Relationship between serum TNF-α, IL-6, and IL- 10 levels and disease severity, and changes in the cytokines after treatment in patients with bacterial community-acquired pneumonia

Author

Dao*, Bang Ngoc, primary, Le, Hien Dieu Thi, additional, Nguyen*, Kien Xuan, additional, Viet, Tien Tran, additional, Tran, Cuong Tan, additional, Luong, Thuc Cong, additional, Le, Tuan Dinh, additional, Nguyen, Son Tien, additional, Vu, Hoan Ngoc, additional, Pham, Nhung Thi Kim, additional, Nguyen, An Van, additional, Dinh, Hoa Trung, additional, Tong, Thang Tho, additional, Nguyen, Mai Ly Thi, additional, and Ta*, Thang Ba, additional

Published
2023
Full Text
View/download PDF

10. Opuntia ficus-indica (L.): An Overview of the Recent Application and Opportunities in Food.

Author

Ha, Quynh T. T., Nguyen, Khanh K., Le, Anh N., Vu, Hoan T., and Nguyen, Tuan N.

Subjects
OPUNTIA ficus-indica, PRICKLY pears, HYPOGLYCEMIA, POLYPHENOLS, ANTIOXIDANTS
Abstract

Opuntia ficus-indica (OFI, prickly pears, nopal cactus) has been used as a food, in beverages, besides prickly pears's natural betalain pigment serves as a food colorant. The abundant biological components of nopal cactus, including polyphenols, flavonoids, and other related compounds that exhibit therapeutic like, hypoglycemia management, anti-infection, anti-inflammatory, and antioxidation. Its versatility is remarkable, finding applications in pharmaceuticals, cosmetics, human and livestock nutrition, alternative fuels, construction, erosion control, and animal care. Recent studies highlight its potential to inhibit the growth of cervical, ovarian, and bladder cancer cells in vitro. In vivo tests on mice demonstrated decreased tumor growth in the ovarian cancer model. However, more meticulously designed clinical trials are required, utilizing phytochemically characterized preparations. Opuntia ficus-indica recast an exceptional safety and tolerability profile, underscoring its potential as a versatile and health-promoting resource. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Supplemental Material, sj-pdf-1-ccx-10.1177_1073274821989320 - Risk factors of Pancreatic Cancer in Vietnam: A Matched Case–Control Hospital-Based Study

Author

Tran, Thuan Van, Dao, Tu Van, Khac-Dung Nguyen, TA, To Van, Vu, Khanh Truong, Trinh, Son Hong, Nguyen, Hoang Cong, Bui, Oanh Thi, Nguyen, Quang Tien, Vu, Hoan Duc, Nguyen, Hiep Le, and Tran, Huong Thanh

Subjects
FOS: Clinical medicine, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental Material, sj-pdf-1-ccx-10.1177_1073274821989320 for Risk factors of Pancreatic Cancer in Vietnam: A Matched Case–Control Hospital-Based Study by Thuan Van Tran, Tu Van Dao, Khac-Dung Nguyen, To van TA, Khanh Truong Vu, Son Hong Trinh, Hoang Cong Nguyen, Oanh Thi Bui, Quang Tien Nguyen, Hoan Duc Vu, Hiep Le Nguyen and Huong Thanh Tran in Cancer Control

Published
2021
Full Text
View/download PDF

19. Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

Author

Nguyen, Thuy Phuong, primary, Do, Quyet, additional, Lan, Phan Trong, additional, Dinh, Duc Viet, additional, Khong, Hiep, additional, Hoang, Luong Van, additional, Nguyen, Thuong Vu, additional, Ngoc, Hung Pham, additional, Chu, Men Van, additional, Nguyen, Toan Trong, additional, Pham, Quang Duy, additional, Le, Tri Minh, additional, Trang, Tuyen Thi Ngoc, additional, Dinh, Thanh Thi, additional, Vo, Thuong Van, additional, Vu, Thao Thi Thu, additional, Nguyen, Quynh Bao Phuong, additional, Phan, Vuong Tan, additional, Nguyen, Luong Viet, additional, Nguyen, Giang Truong, additional, Tran, Phong Minh, additional, Nghiem, Thuan Duc, additional, Tran, Tien Viet, additional, Nguyen, Tien Gia, additional, Tran, Tuynh Quang, additional, Nguyen, Linh Tung, additional, Do, Anh Tuan, additional, Nguyen, Dung Dang, additional, Ho, Son Anh, additional, Nguyen, Viet Thanh, additional, Pham, Dung T., additional, Tran, Hieu Ba, additional, Vu, Son Tung, additional, Vu, Hoan Ngoc, additional, Hoang, Cuong Xuan, additional, Hoang, Su Xuan, additional, Do, Trung Minh, additional, Nguyen, Xuan Thanh, additional, Le, Giang Quynh, additional, Tran, Ton, additional, Cao, Thang Minh, additional, Dao, Huy Manh, additional, Nguyen, Thao Thi Thanh, additional, Doan, Uyen Y., additional, Vy, Le Thi Tuong, additional, Tran, Linh Phuong, additional, Nguyen, Ngoc Minh, additional, Nguyen, Ngoc Thu, additional, Pham, Hang Thi Thu, additional, Nguyen, Quan Hoang, additional, Nguyen, Hieu Trung, additional, Nguyen, Hang Le Khanh, additional, Tran, Vinh The, additional, Tran, Mai Thi Nhu, additional, Nguyen, Truc Thi Thanh, additional, Ha, Phat Tan, additional, Huynh, Hieu Trong, additional, Nguyen, Khanh Duy, additional, Ung, Thuan Trong, additional, Doan, Chung Chinh, additional, and Do, Si Minh, additional

Published
2021
Full Text
View/download PDF

24. Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry

Author

Vu, Hoan, Pedro, Liliana, Mak, Tin, McCormick, Brendan, Rowley, Jessica, Liu, Miaomiao, Di Capua, Angela, Williams-Noonan, Billy, Pham, Ngoc B., Pouwer, Rebecca, Nguyen, Bao, Andrews, Katherine T., Skinner-Adams, Tina, Kim, Jessica, Hol, Wim G. J., Hui, Raymond, Crowther, Gregory J., Van Voorhis, Wesley C., and Quinn, Ronald J.

Subjects
Antimalarials, Biological Products, natural products, native mass spectrometry, target identification, fragments, Plasmodium falciparum, malaria, Drug Evaluation, Preclinical, Protozoan Proteins, Featured Article, Mass Spectrometry, Protein Binding
Abstract

Natural products are well known for their biological relevance, high degree of three-dimensionality, and access to areas of largely unexplored chemical space. To shape our understanding of the interaction between natural products and protein targets in the postgenomic era, we have used native mass spectrometry to investigate 62 potential protein targets for malaria using a natural-product-based fragment library. We reveal here 96 low-molecular-weight natural products identified as binding partners of 32 of the putative malarial targets. Seventy-nine (79) fragments have direct growth inhibition on Plasmodium falciparum at concentrations that are promising for the development of fragment hits against these protein targets. This adds a fragment library to the published HTS active libraries in the public domain.

Published
2018

25. On a final value problem for a biparabolic equation with statistical discrete data

Author

Tuan, Nguyen Huy, Thach, Tran Ngoc, Vu, Hoan Luu Cam, and Can, Nguyen Huu

Abstract

This article is devoted to the study of final value problems for biparabolic equation with discrete data in two cases as the linear source and the nonlinear source, respectively. In each of the cases, we show the instability of the solutions and then establish approximate solutions by applying some regularization methods. In addition, the convergence estimates and numerical experiments showing the flexibility of those methods are given.

Published
2020
Full Text
View/download PDF

26. Controlling the spontaneous emission rate of quantum wells in rolled-up hyperbolic metamaterials

Author

Schulz, K. Marvin, Vu, Hoan, Schwaiger, Stephan, Rottler, Andreas, Korn, Tobias, Sonnenberg, David, Kipp, Tobias, Mendach, Stefan, Schulz, K. Marvin, Vu, Hoan, Schwaiger, Stephan, Rottler, Andreas, Korn, Tobias, Sonnenberg, David, Kipp, Tobias, and Mendach, Stefan

Abstract

We experimentally demonstrate the enhancement of the spontaneous emission rate of GaAs quantum wells embedded in rolled-up metamaterials. We fabricate microtubes whose walls consist of alternating Ag and (In)(Al)GaAs layers with incorporated active GaAs quantum-well structures. By variation of the layer thickness ratio of the Ag and (In)(Al)GaAs layers we control the effective permittivity tensor of the metamaterial according to an effective medium approach. Thereby, we can design samples with elliptic or hyperbolic dispersion. Time-resolved low temperature photoluminescence spectroscopy supported by finite-difference time-domain simulations reveal a decrease of the quantum well's spontaneous emission lifetime in our metamaterials as a signature of the crossover from elliptic to hyperbolic dispersion., Deutsche Forschungsgemeinschaft (DFG)

Published
2020

27. On a final value problem for a biparabolic equation with statistical discrete data.

Author

Tuan, Nguyen Huy, Thach, Tran Ngoc, Cam Vu, Hoan Luu, and Can, Nguyen Huu

Subjects
STATISTICS, EQUATIONS
Abstract

This article is devoted to the study of final value problems for biparabolic equation with discrete data in two cases as the linear source and the nonlinear source, respectively. In each of the cases, we show the instability of the solutions and then establish approximate solutions by applying some regularization methods. In addition, the convergence estimates and numerical experiments showing the flexibility of those methods are given. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Author

Phillips, Margaret A., Van Voorhis, Wesley C., Adams, John H., Adelfio, Roberto, Ahyong, Vida, Akabas, Myles H., Alano, Pietro, Alday, Aintzane, Alsibaee, Aishah, Alzualde, Ainhoa, Andrews, Katherine T., Avery, Simon V., Avery, Vicky M., Ayong, Lawrence, Baker, Mark, Baker, Stephen, Ben Mamoun, Choukri, Bhatia, Sangeeta, Bickle, Quentin, Bounaadja, Lotfi, Bowling, Tana, Boucher, Lauren E., Boyom, Fabrice F., Brea, Jose, Brennan, Marian, Burton, Audrey, Caffrey, Conor R., Camarda, Grazia, Carrasquilla, Manuela, Carter, Dee, Belen Cassera, Maria, Chih-Chien Cheng, Ken, Chindaudomsate, Worathad, Chubb, Anthony, Colon, Beatrice L., Corbett, Yolanda, Crowther, Gregory J., Cowan, Noemi, Le Dang, Na, Delves, Michael, DeRisi, Joseph L., Du, Alan Y., Duffy, Sandra, Abd El-Salam El-Sayed, Shimaa, Ferdig, Michael T., Fidock, David A., Florent, Isabelle, Fokou, Patrick V. T., Galstian, Ani, Gamo, Francisco Javier, Gokool, Suzanne, Gold, Ben, Golub, Todd, Goldgof, Gregory M., Guha, Rajarshi, Guiguemde, W. Armand, Gural, Nil, Guy, R. Kiplin, Hansen, Michael A. E., Hanson, Kirsten K., Hemphill, Andrew, Hooft van Huijsduijnen, Rob, Horii, Takaaki, Horrocks, Paul, Hughes, Tyler B., Huston, Christopher, Igarashi, Ikuo, Ingram-Sieber, Katrin, Itoe, Maurice A., Jadhav, Ajit, Naranuntarat Jensen, Amornrat, Jensen, Laran T., Jiang, Rays H.Y., Kaiser, Annette, Keiser, Jennifer, Ketas, Thomas, Kicka, Sebastien, Kim, Sunyoung, Kirk, Kiaran, Kumar, Vidya P., Kyle, Dennis E., Lafuente, Maria Jose, Landfear, Scott, Lee, Nathan, Lee, Sukjun, Lehane, Adele M., Li, Fengwu, Little, David, Liu, Liqiong, Loza, Maria I., Lubar, Aristea, Lucantoni, Leonardo, Lucet, Isabelle, Maes, Louis, Mancama, Dalu, Mansour, Nuha R., March, Sandra, McGowan, Sheena, Medina Vera, Iset, Meister, Stephan, Mercer, Luke, Mestres, Jordi, Mfopa, Alvine N., Misra, Raj N., Moon, Seunghyun, Moore, John P., Morais Rodrigues da Costa, Francielly, Muriana, Arantza, Nakazawa Hewitt, Stephen, Nare, Bakela, Nathan, Carl, Narraidoo, Nathalie, Nawaratna, Sujeevi, Ojo, Kayode K., Ortiz, Diana, Panic, Gordana, Papadatos, George, Parapini, Silvia, Patra, Kailash, Pham, Ngoc, Prats, Sarah, Plouffe, David M., Poulsen, Sally-Ann, Pradhan, Anupam, Quevedo, Celia, Quinn, Ronald J., Rice, Christopher A., Abdo Rizk, Mohamed, Ruecker, Andrea, St. Onge, Robert, Salgado Ferreira, Rafaela, Samra, Jasmeet, Robinett, Natalie G., Schlecht, Ulrich, Schmitt, Marjorie, Silva Villela, Filipe, Silvestrini, Francesco, Sinden, Robert, Smith, Dennis A., Soldati, Thierry, Stamm, Serge Maximilian, Sullivan, David J., Sullivan, William, Suresh, Sundari, Suzuki, Brian M., Suzuki, Yo, Swamidass, S. Joshua, Taramelli, Donatella, Tchokouaha, Lauve R.Y., Theron, Anjo, Thomas, David, Tonissen, Kathryn F., Townson, Simon, Tripathi, Abhai K., Trofimov, Valentin, Udenze, Kenneth O., Ullah, Imran, Vallieres, Cindy, Vigil, Edgar, Vinetz, Joseph M., Voong Vinh, Phat, Vu, Hoan, Watanabe, Nao-aki, Weatherby, Kate, White, Pamela M., Wilks, Andrew F., Winzeler, Elizabeth A., Wojcik, Edward, Wree, Melanie, Wu, Wesley, Yokoyama, Naoaki, Zollo, Paul H. A., Abla, Nada, Blasco, Benjamin, Burrows, Jeremy, Leroy, Didier, Spangenberg, Thomas, Wells, Timothy, and Willis, Paul A.

Abstract

A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery. The Medicines for Malaria Venture Malaria Box is a collection of over 400 compounds representing families of structures identified in phenotypic screens of pharmaceutical and academic libraries against the Plasmodium falciparum malaria parasite. The set has now been distributed to almost 200 research groups globally in the last two years, with the only stipulation that information from the screens is deposited in the public domain. This paper reports for the first time on 236 screens that have been carried out against the Malaria Box and compares these results with 55 assays that were previously published, in a format that allows a meta-analysis of the combined dataset. The combined biochemical and cellular assays presented here suggest mechanisms of action for 135 (34%) of the compounds active in killing multiple life-cycle stages of the malaria parasite, including asexual blood, liver, gametocyte, gametes and insect ookinete stages. In addition, many compounds demonstrated activity against other pathogens, showing hits in assays with 16 protozoa, 7 helminths, 9 bacterial and mycobacterial species, the dengue fever mosquito vector, and the NCI60 human cancer cell line panel of 60 human tumor cell lines. Toxicological, pharmacokinetic and metabolic properties were collected on all the compounds, assisting in the selection of the most promising candidates for murine proof-of-concept experiments and medicinal chemistry programs. The data for all of these assays are presented and analyzed to show how outstanding leads for many indications can be selected. These results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications. Another lesson is that when multiple screens from different groups are run on the same library, results can be integrated quickly to select the most valuable starting points for subsequent medicinal chemistry efforts.

Published
2016

31. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors

Author

Maresca, Alfonso, Temperini, Claudia, Vu, Hoan, Pham, Ngoc B., Quinn, Ronald J., and Supuran, Claudiu T.

Subjects
Coumarins -- Chemical properties, Coumarins -- Structure, Hydrolysis -- Analysis, Organometallic compounds -- Structure, Organometallic compounds -- Chemical properties, X-ray crystallography -- Usage, Zinc -- Chemical properties, Chemistry
Abstract

The X-ray crystal structure of the adduct between the zinc metalloenzyme carbonic anhydrase II (CA) with the natural product coumarin derivative 6-(1S-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one has shown the coumarin hydrolysis product bound within the enzyme active site. Several structurally simple coumarin scaffolds are shown to inhibit all 13 catalytically active mammalian CA isoforms, where inhibition is time dependent.

Published
2009

33. Natural Product and Fragment-Based Drug Discovery Against Malaria Protein Targets by Native Mass Spectrometry

Author

Quinn, Ronald, Brown, Christopher, Vu, Hoan, Pedro, Liliana Antunes, Quinn, Ronald, Brown, Christopher, Vu, Hoan, and Pedro, Liliana Antunes

Abstract

Full Text, Thesis (PhD Doctorate), Doctor of Philosophy (PhD), School of Natural Sciences, Science, Environment, Engineering and Technology, Malaria control interventions have been effective in reducing malaria incidence and mortality rates globally over the last decade. However, increasing resistance of Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax), the two most prevalent parasite species, to the most used antimalarial drugs, threatens to halt the progress. Given the current limited arsenal of antimalarial drugs has been inspired by natural product scaffolds, these have the potential to be the source of new and structurally different antimalarial drugs, acting through novel mechanisms of action, that are urgently needed. Translating the structural and biologically relevant diversity of natural products into an efficient and effective drug development process is, nonetheless, not trivial. Fragment-based drug discovery (FBDD) is a relatively recent and promising approach for drug discovery. It involves the identification of small molecular weight compounds, called fragments, that weakly bind to a biological target and their elaboration through chemical synthesis to produce high affinity and selective drugs. For a rational and effective elaboration process, structural and thermodynamic information are essential.

Published
2017

34. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Author

Institute for Medical Engineering and Science, Harvard University--MIT Division of Health Sciences and Technology, Bhatia, Sangeeta N, Van Voorhis, Wesley C., Adams, John H., Adelfio, Roberto, Ahyong, Vida, Akabas, Myles H., Alano, Pietro, Alday, Aintzane, Yesmalie, Alemán Resto, Alsibaee, Aishah, Alzualde, Ainhoa, Andrews, Katherine T., Avery, Simon V., Avery, Vicky M., Ayong, Lawrence, Baker, Mark, Baker, Stephen, Ben Mamoun, Choukri, Bickle, Quentin, Bounaadja, Lotfi, Bowling, Tana, Bosch, Jürgen, Boucher, Lauren E., Boyom, Fabrice F., Brea, Jose, Brennan, Marian, Burton, Audrey, Caffrey, Conor R., Camarda, Grazia, Carrasquilla, Manuela, Carter, Dee, Cassera, Maria Belen, Ken, Chih-Chien Cheng, Chindaudomsate, Worathad, Chubb, Anthony, Colon, Beatrice L., Colón-López, Daisy D., Corbett, Yolanda, Crowther, Gregory J., Cowan, Noemi, D’Alessandro, Sarah, Le Dang, Na, Delves, Michael, DeRisi, Joseph L., Du, Alan Y., Duffy, Sandra, Abd El-Salam El-Sayed, Shimaa, Ferdig, Michael T., Fernández Robledo, José A., Fidock, David A., Florent, Isabelle, Fokou, Patrick V. T., Galstian, Ani, Gamo, Francisco Javier, Gokool, Suzanne, Gold, Ben, Golub, Todd, Goldgof, Gregory M., Guha, Rajarshi, Guiguemde, W. Armand, Gural, Nil, Guy, R. Kiplin, Hansen, Michael A. E., Hanson, Kirsten K., Hemphill, Andrew, Hooft van Huijsduijnen, Rob, Horii, Takaaki, Horrocks, Paul, Hughes, Tyler B., Huston, Christopher, Igarashi, Ikuo, Ingram-Sieber, Katrin, Itoe, Maurice A., Jadhav, Ajit, Naranuntarat Jensen, Amornrat, Jensen, Laran T., Jiang, Rays H. Y., Kaiser, Annette, Keiser, Jennifer, Ketas, Thomas, Kicka, Sebastien, Kim, Sunyoung, Kirk, Kiaran, Kumar, Vidya P., Kyle, Dennis E., Lafuente, Maria Jose, Landfear, Scott, Lee, Nathan, Lee, Sukjun, Lehane, Adele M., Li, Fengwu, Little, David, Liu, Liqiong, Llinás, Manuel, Loza, Maria I., Lubar, Aristea, Lucantoni, Leonardo, Lucet, Isabelle, Maes, Louis, Mancama, Dalu, Mansour, Nuha R., March, Sandra, McGowan, Sheena, Medina Vera, Iset, Meister, Stephan, Mercer, Luke, Mestres, Jordi, Mfopa, Alvine N., Misra, Raj N., Moon, Seunghyun, Moore, John P., Morais Rodrigues da Costa, Francielly, Müller, Joachim, Muriana, Arantza, Nakazawa Hewitt, Stephen, Nare, Bakela, Nathan, Carl, Narraidoo, Nathalie, Nawaratna, Sujeevi, Ojo, Kayode K., Ortiz, Diana, Panic, Gordana, Papadatos, George, Parapini, Silvia, Patra, Kailash, Pham, Ngoc, Prats, Sarah, Plouffe, David M., Poulsen, Sally-Ann, Pradhan, Anupam, Quevedo, Celia, Quinn, Ronald J., Rice, Christopher A., Ruecker, Andrea, St. Onge, Robert, Salgado Ferreira, Rafaela, Samra, Jasmeet, Robinett, Natalie G., Schlecht, Ulrich, Schmitt, Marjorie, Silva Villela, Filipe, Silvestrini, Francesco, Sinden, Robert, Smith, Dennis A., Soldati, Thierry, Spitzmüller, Andreas, Stamm, Serge Maximilian, Sullivan, David J., Sullivan, William, Suresh, Sundari, Suzuki, Brian M., Suzuki, Yo, Swamidass, S. Joshua, Taramelli, Donatella, Tchokouaha, Lauve R. Y., Theron, Anjo, Thomas, David, Tonissen, Kathryn F., Townson, Simon, Tripathi, Abhai K., Trofimov, Valentin, Udenze, Kenneth O., Ullah, Imran, Vallieres, Cindy, Vigil, Edgar, Vinetz, Joseph M., Voong Vinh, Phat, Vu, Hoan, Watanabe, Nao-aki, Weatherby, Kate, White, Pamela M., Wilks, Andrew F., Winzeler, Elizabeth A., Wojcik, Edward, Wree, Melanie, Wu, Wesley, Yokoyama, Naoaki, Zollo, Paul H. A., Abla, Nada, Blasco, Benjamin, Burrows, Jeremy, Laleu, Benoît, Leroy, Didier, Spangenberg, Thomas, Wells, Timothy, Willis, Paul A., Institute for Medical Engineering and Science, Harvard University--MIT Division of Health Sciences and Technology, Bhatia, Sangeeta N, Van Voorhis, Wesley C., Adams, John H., Adelfio, Roberto, Ahyong, Vida, Akabas, Myles H., Alano, Pietro, Alday, Aintzane, Yesmalie, Alemán Resto, Alsibaee, Aishah, Alzualde, Ainhoa, Andrews, Katherine T., Avery, Simon V., Avery, Vicky M., Ayong, Lawrence, Baker, Mark, Baker, Stephen, Ben Mamoun, Choukri, Bickle, Quentin, Bounaadja, Lotfi, Bowling, Tana, Bosch, Jürgen, Boucher, Lauren E., Boyom, Fabrice F., Brea, Jose, Brennan, Marian, Burton, Audrey, Caffrey, Conor R., Camarda, Grazia, Carrasquilla, Manuela, Carter, Dee, Cassera, Maria Belen, Ken, Chih-Chien Cheng, Chindaudomsate, Worathad, Chubb, Anthony, Colon, Beatrice L., Colón-López, Daisy D., Corbett, Yolanda, Crowther, Gregory J., Cowan, Noemi, D’Alessandro, Sarah, Le Dang, Na, Delves, Michael, DeRisi, Joseph L., Du, Alan Y., Duffy, Sandra, Abd El-Salam El-Sayed, Shimaa, Ferdig, Michael T., Fernández Robledo, José A., Fidock, David A., Florent, Isabelle, Fokou, Patrick V. T., Galstian, Ani, Gamo, Francisco Javier, Gokool, Suzanne, Gold, Ben, Golub, Todd, Goldgof, Gregory M., Guha, Rajarshi, Guiguemde, W. Armand, Gural, Nil, Guy, R. Kiplin, Hansen, Michael A. E., Hanson, Kirsten K., Hemphill, Andrew, Hooft van Huijsduijnen, Rob, Horii, Takaaki, Horrocks, Paul, Hughes, Tyler B., Huston, Christopher, Igarashi, Ikuo, Ingram-Sieber, Katrin, Itoe, Maurice A., Jadhav, Ajit, Naranuntarat Jensen, Amornrat, Jensen, Laran T., Jiang, Rays H. Y., Kaiser, Annette, Keiser, Jennifer, Ketas, Thomas, Kicka, Sebastien, Kim, Sunyoung, Kirk, Kiaran, Kumar, Vidya P., Kyle, Dennis E., Lafuente, Maria Jose, Landfear, Scott, Lee, Nathan, Lee, Sukjun, Lehane, Adele M., Li, Fengwu, Little, David, Liu, Liqiong, Llinás, Manuel, Loza, Maria I., Lubar, Aristea, Lucantoni, Leonardo, Lucet, Isabelle, Maes, Louis, Mancama, Dalu, Mansour, Nuha R., March, Sandra, McGowan, Sheena, Medina Vera, Iset, Meister, Stephan, Mercer, Luke, Mestres, Jordi, Mfopa, Alvine N., Misra, Raj N., Moon, Seunghyun, Moore, John P., Morais Rodrigues da Costa, Francielly, Müller, Joachim, Muriana, Arantza, Nakazawa Hewitt, Stephen, Nare, Bakela, Nathan, Carl, Narraidoo, Nathalie, Nawaratna, Sujeevi, Ojo, Kayode K., Ortiz, Diana, Panic, Gordana, Papadatos, George, Parapini, Silvia, Patra, Kailash, Pham, Ngoc, Prats, Sarah, Plouffe, David M., Poulsen, Sally-Ann, Pradhan, Anupam, Quevedo, Celia, Quinn, Ronald J., Rice, Christopher A., Ruecker, Andrea, St. Onge, Robert, Salgado Ferreira, Rafaela, Samra, Jasmeet, Robinett, Natalie G., Schlecht, Ulrich, Schmitt, Marjorie, Silva Villela, Filipe, Silvestrini, Francesco, Sinden, Robert, Smith, Dennis A., Soldati, Thierry, Spitzmüller, Andreas, Stamm, Serge Maximilian, Sullivan, David J., Sullivan, William, Suresh, Sundari, Suzuki, Brian M., Suzuki, Yo, Swamidass, S. Joshua, Taramelli, Donatella, Tchokouaha, Lauve R. Y., Theron, Anjo, Thomas, David, Tonissen, Kathryn F., Townson, Simon, Tripathi, Abhai K., Trofimov, Valentin, Udenze, Kenneth O., Ullah, Imran, Vallieres, Cindy, Vigil, Edgar, Vinetz, Joseph M., Voong Vinh, Phat, Vu, Hoan, Watanabe, Nao-aki, Weatherby, Kate, White, Pamela M., Wilks, Andrew F., Winzeler, Elizabeth A., Wojcik, Edward, Wree, Melanie, Wu, Wesley, Yokoyama, Naoaki, Zollo, Paul H. A., Abla, Nada, Blasco, Benjamin, Burrows, Jeremy, Laleu, Benoît, Leroy, Didier, Spangenberg, Thomas, Wells, Timothy, and Willis, Paul A.

Abstract

A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery. The Medicines for Malaria Venture Malaria Box is a collection of over 400 compounds representing families of structures identified in phenotypic screens of pharmaceutical and academic libraries against the Plasmodium falciparum malaria parasite. The set has now been distributed to almost 200 research groups globally in the last two years, with the only stipulation that information from the screens is deposited in the public domain. This paper reports for the first time on 236 screens that have been carried out against the Malaria Box and compares these results with 55 assays that were previously published, in a format that allows a meta-analysis of the combined dataset. The combined biochemical and cellular assays presented here suggest mechanisms of action for 135 (34%) of the compounds active in killing multiple life-cycle stages of the malaria parasite, including asexual blood, liver, gametocyte, gametes and insect ookinete stages. In addition, many compounds demonstrated activity against other pathogens, showing hits in assays with 16 protozoa, 7 helminths, 9 bacterial and mycobacterial species, the dengue fever mosquito vector, and the NCI60 human cancer cell line panel of 60 human tumor cell lines. Toxicological, pharmacokinetic and metabolic properties were collected on all the compounds, assisting in the selection of the most promising candidates for murine proof-of-concept experiments and medicinal chemis

Published
2017

36. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Author

Van Voorhis, Wesley C., primary, Adams, John H., additional, Adelfio, Roberto, additional, Ahyong, Vida, additional, Akabas, Myles H., additional, Alano, Pietro, additional, Alday, Aintzane, additional, Alemán Resto, Yesmalie, additional, Alsibaee, Aishah, additional, Alzualde, Ainhoa, additional, Andrews, Katherine T., additional, Avery, Simon V., additional, Avery, Vicky M., additional, Ayong, Lawrence, additional, Baker, Mark, additional, Baker, Stephen, additional, Ben Mamoun, Choukri, additional, Bhatia, Sangeeta, additional, Bickle, Quentin, additional, Bounaadja, Lotfi, additional, Bowling, Tana, additional, Bosch, Jürgen, additional, Boucher, Lauren E., additional, Boyom, Fabrice F., additional, Brea, Jose, additional, Brennan, Marian, additional, Burton, Audrey, additional, Caffrey, Conor R., additional, Camarda, Grazia, additional, Carrasquilla, Manuela, additional, Carter, Dee, additional, Belen Cassera, Maria, additional, Chih-Chien Cheng, Ken, additional, Chindaudomsate, Worathad, additional, Chubb, Anthony, additional, Colon, Beatrice L., additional, Colón-López, Daisy D., additional, Corbett, Yolanda, additional, Crowther, Gregory J., additional, Cowan, Noemi, additional, D’Alessandro, Sarah, additional, Le Dang, Na, additional, Delves, Michael, additional, DeRisi, Joseph L., additional, Du, Alan Y., additional, Duffy, Sandra, additional, Abd El-Salam El-Sayed, Shimaa, additional, Ferdig, Michael T., additional, Fernández Robledo, José A., additional, Fidock, David A., additional, Florent, Isabelle, additional, Fokou, Patrick V. T., additional, Galstian, Ani, additional, Gamo, Francisco Javier, additional, Gokool, Suzanne, additional, Gold, Ben, additional, Golub, Todd, additional, Goldgof, Gregory M., additional, Guha, Rajarshi, additional, Guiguemde, W. Armand, additional, Gural, Nil, additional, Guy, R. Kiplin, additional, Hansen, Michael A. E., additional, Hanson, Kirsten K., additional, Hemphill, Andrew, additional, Hooft van Huijsduijnen, Rob, additional, Horii, Takaaki, additional, Horrocks, Paul, additional, Hughes, Tyler B., additional, Huston, Christopher, additional, Igarashi, Ikuo, additional, Ingram-Sieber, Katrin, additional, Itoe, Maurice A., additional, Jadhav, Ajit, additional, Naranuntarat Jensen, Amornrat, additional, Jensen, Laran T., additional, Jiang, Rays H. Y., additional, Kaiser, Annette, additional, Keiser, Jennifer, additional, Ketas, Thomas, additional, Kicka, Sebastien, additional, Kim, Sunyoung, additional, Kirk, Kiaran, additional, Kumar, Vidya P., additional, Kyle, Dennis E., additional, Lafuente, Maria Jose, additional, Landfear, Scott, additional, Lee, Nathan, additional, Lee, Sukjun, additional, Lehane, Adele M., additional, Li, Fengwu, additional, Little, David, additional, Liu, Liqiong, additional, Llinás, Manuel, additional, Loza, Maria I., additional, Lubar, Aristea, additional, Lucantoni, Leonardo, additional, Lucet, Isabelle, additional, Maes, Louis, additional, Mancama, Dalu, additional, Mansour, Nuha R., additional, March, Sandra, additional, McGowan, Sheena, additional, Medina Vera, Iset, additional, Meister, Stephan, additional, Mercer, Luke, additional, Mestres, Jordi, additional, Mfopa, Alvine N., additional, Misra, Raj N., additional, Moon, Seunghyun, additional, Moore, John P., additional, Morais Rodrigues da Costa, Francielly, additional, Müller, Joachim, additional, Muriana, Arantza, additional, Nakazawa Hewitt, Stephen, additional, Nare, Bakela, additional, Nathan, Carl, additional, Narraidoo, Nathalie, additional, Nawaratna, Sujeevi, additional, Ojo, Kayode K., additional, Ortiz, Diana, additional, Panic, Gordana, additional, Papadatos, George, additional, Parapini, Silvia, additional, Patra, Kailash, additional, Pham, Ngoc, additional, Prats, Sarah, additional, Plouffe, David M., additional, Poulsen, Sally-Ann, additional, Pradhan, Anupam, additional, Quevedo, Celia, additional, Quinn, Ronald J., additional, Rice, Christopher A., additional, Abdo Rizk, Mohamed, additional, Ruecker, Andrea, additional, St. Onge, Robert, additional, Salgado Ferreira, Rafaela, additional, Samra, Jasmeet, additional, Robinett, Natalie G., additional, Schlecht, Ulrich, additional, Schmitt, Marjorie, additional, Silva Villela, Filipe, additional, Silvestrini, Francesco, additional, Sinden, Robert, additional, Smith, Dennis A., additional, Soldati, Thierry, additional, Spitzmüller, Andreas, additional, Stamm, Serge Maximilian, additional, Sullivan, David J., additional, Sullivan, William, additional, Suresh, Sundari, additional, Suzuki, Brian M., additional, Suzuki, Yo, additional, Swamidass, S. Joshua, additional, Taramelli, Donatella, additional, Tchokouaha, Lauve R. Y., additional, Theron, Anjo, additional, Thomas, David, additional, Tonissen, Kathryn F., additional, Townson, Simon, additional, Tripathi, Abhai K., additional, Trofimov, Valentin, additional, Udenze, Kenneth O., additional, Ullah, Imran, additional, Vallieres, Cindy, additional, Vigil, Edgar, additional, Vinetz, Joseph M., additional, Voong Vinh, Phat, additional, Vu, Hoan, additional, Watanabe, Nao-aki, additional, Weatherby, Kate, additional, White, Pamela M., additional, Wilks, Andrew F., additional, Winzeler, Elizabeth A., additional, Wojcik, Edward, additional, Wree, Melanie, additional, Wu, Wesley, additional, Yokoyama, Naoaki, additional, Zollo, Paul H. A., additional, Abla, Nada, additional, Blasco, Benjamin, additional, Burrows, Jeremy, additional, Laleu, Benoît, additional, Leroy, Didier, additional, Spangenberg, Thomas, additional, Wells, Timothy, additional, and Willis, Paul A., additional

Published
2016
Full Text
View/download PDF

38. Bioaffinity Fourier Transform Ion Cyclotron Resonance Mass Spectrometry for Direct Screening of Natural Product Extracts

Author

Vu, Hoan

Subjects
Natural product extracts, Biological activities, Electrospray ionization mass spectrometry, Fourier transform spectroscopy
Abstract

The search for new drugs in natural products involves the screening of natural product extracts on therapeutic targets for the presence of active compounds and subsequent investigation of their biological activities. Towards this end, a rapid and effective strategy to identify the noncovalent interactions between active ligands from natural product extracts with therapeutic protein targets without false positive or negative results is critical. The current thesis presents the outcomes of research exploring a novel approach of biological screening of natural product extracts using bioaffinity ESI-FTICR-MS as a detection means. A research plan containing three major steps has been undertaken in this study. Step one examines the current challenges in identifying protein complexes by ESI-MS and developing optimized conditions for ESI-FTICR-MS. Step two involves the development of methods for identifying complexes of targets with various molecular mass values (600 – 66,000 Da) in the setting of crude extracts. Step three uses these methods to screen natural product extracts and identify active natural product compound – protein complexes, obtaining accurate molecular mass of active compounds and their mass fingerprint. On this basis, a mass-directed purification experiment was performed to isolate the identified active compounds. The binding of the pure active compounds with the protein target was then confirmed by competition experiments with a specific inhibitor of the protein. The procedure to achieve the optimal ESI-MS condition for detecting protein - small molecule complex has been successfully developed using bCA II as the test target protein and fractional factorial design (FFD) approach. Key instrumental factors controlling the desolvation process, as well as the interactions between these factors, have been identified using FFD experiment. It has been found that flow rate, nebulizer gas pressure and drying gas flow rate are factors that greatly affect the sensitivity of the complex detection. Capillary exit voltage also has a great effect on the desolvation in vacuum and on the preservation of the complex. These factors have been found to interact with each other and contribute to the final response, and therefore, have been incorporated in a second FFD experiment which focuses on minimum moment aberration. It has been found that the best condition is achieved when the capillary exit voltage is at the highest setting, and the flow rate, drying gas flow rate and nebulizing gas are at medium settings. The development of ESI-FTICR-MS methods for identifying noncovalent complexes in the environment of crude extracts has been accomplished using targets with various molecular mass values. In particular, ESI-FTICR-MS has been used to successfully detect hemin (< 1 kDa) and its complex with artemisinin. Accurate mass for artemisinin has been deduced with high resolution (deviation from theoretical value of less than 5 ppm). Screening 50 plant and marine sponge biota with hemin returned four active extracts. One of the four active natural product compounds had the molecular mass very close to artemisinin (Δ = 0.002 Da). The artemisinin identity of the active component has been confirmed using the MS2 pattern of artemisinin and the suspect artemisinin active component. A flavonoid was also detected in one of the active extracts and the structure elucidation of this active flavonoid has been proposed by comparing its diagnostic fragmentation patterns in multiple stage MS with those of other flavonones and flavonols. The first MS3 fragment ions of these 4 flavones and 2 flavonols are also presented in this study. The third and fourth active compounds have been isolated based on their accurate mass information using mass-directed purification. Their structures have also been determined by NMR. They are diacarnoic acids and are epi-isomers at position 3. MS2 experiments have been performed and can discriminate between these two compounds. Methods have also been developed for proteins having higher molecular masses using three target proteins ranging from 13 to 66 kDa. Using these methods, ESI-FTICR-MS or SEC-FTICR-MS have successfully identified these proteins and their complexes in a clean matrix, as well as in a natural product extract matrix. The use of microdialysis and SEC has been found to be a suitable method for protein desalting and buffer exchange, and for natural product extract filtering. The results support the conclusion that the ability of FTICR-MS to give accurate molecular mass of the inhibitors represents a powerful means for screening natural product extracts in a drug discovery process of finding diversified small molecule inhibitors. The methods developed for both direct infusion and online SEC-FTICR-MS have been successfully employed to screen 85 raw methanolic plant extracts with bCA II. A noncovalent complex has been detected and the active compound which binds to bCA II is identified. The specificity of the binding has also been confirmed by competition experiments with a specific inhibitor of the target protein. The outcomes of this work have been reported in the Journal of Biomolecular Screening (first published online on March 18, 2008). One of the key advantages of using ESI-FTICR-MS and associated methods is that the screening of the crude extracts is carried out without any preparation work such as pre-chromatographed, or pre-purification steps, thus avoiding any contamination which may lead to false positive or negative results. Information on the exact mass of the active compound also provides insights into the chemical composition or structural class of the compounds, thus shortening the long process of lead identification and allowing rapid mass-directed purification to isolate the active compounds. The demonstration of a coupled SEC-ESI-FTICR-MS procedure is superior to a batch method assay, whereby crude extracts are fractionated and subsequently bio-assayed until the active compound is found. Furthermore, this approach yields molecular masses in real time allowing subsequent mass-directed purification.

Published
2009
Full Text
View/download PDF

39. Protocole de qualification de modeles d'hysteresis statiques et dynamiques pour logiciel de conception Reluctool

Author

Do, Vu Hoan, Ampère, Publications, Ampère (AMPERE), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de Génie Electrique de Grenoble (G2ELab), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Schneider, and Entreprise industrielle

Subjects
[SPI.NRJ]Engineering Sciences [physics]/Electric power, [SPI.NRJ] Engineering Sciences [physics]/Electric power
Abstract

Texte complet : http://www.jcge2008.ec-lyon.fr/web_JCGE08/papiers/JCGE08_Thai_Phuong_DO.pdf; National audience; Cet article présente la démarche de qualification de modèles d'hystérésis statiques et dynamiques qui permettent de modéliser aussi bien les caractéristiques hystérétiques des matériaux magnétiques en statique ainsi que leur comportement dynamique quand la fréquence augmente. Le logiciel de conception Reluctool intégrera plusieurs modèles d'hystérésis statiques et dynamiques, ceux-ci devront impérativement être testés pour tester leur précision, robustesse, domaine de validité,.... La suite de l'article présente un modèle dénommé modèle global composé de modèles d'hystérésis statiques et dynamiques. Ce modèle simple et rapide a été appliqué pour modéliser les tôles FeSi GO. Les résultats en statique et en dynamique sont présentés et commentés.

Published
2008

40. Towards an approach for trust negotiation

Author

Vu, Hoan, Jaillon, Philippe, Roelens, Marc, Serpaggi, Xavier, Six, Grégory, Département Réseaux, Information, Multimédia (RIM-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), and Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre G2I

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2007

42. Experimental Strategies for Functional Annotation and Metabolism Discovery: Targeted Screening of Solute Binding Proteins and Unbiased Panning of Metabolomes

Author

Vetting, Matthew W., primary, Al-Obaidi, Nawar, additional, Zhao, Suwen, additional, San Francisco, Brian, additional, Kim, Jungwook, additional, Wichelecki, Daniel J., additional, Bouvier, Jason T., additional, Solbiati, Jose O., additional, Vu, Hoan, additional, Zhang, Xinshuai, additional, Rodionov, Dmitry A., additional, Love, James D., additional, Hillerich, Brandan S., additional, Seidel, Ronald D., additional, Quinn, Ronald J., additional, Osterman, Andrei L., additional, Cronan, John E., additional, Jacobson, Matthew P., additional, Gerlt, John A., additional, and Almo, Steven C., additional

Published
2015
Full Text
View/download PDF

43. Bioaffinity Fourier Transform Ion Cyclotron Resonance Mass Spectrometry for Direct Screening of Natural Product Extracts

Author

Quinn, Ronald, Vu, Hoan, Quinn, Ronald, and Vu, Hoan

Abstract

Full Text, Thesis (PhD Doctorate), Doctor of Philosophy (PhD), School of Science, Science, Environment, Engineering and Technology, The search for new drugs in natural products involves the screening of natural product extracts on therapeutic targets for the presence of active compounds and subsequent investigation of their biological activities. Towards this end, a rapid and effective strategy to identify the noncovalent interactions between active ligands from natural product extracts with therapeutic protein targets without false positive or negative results is critical. The current thesis presents the outcomes of research exploring a novel approach of biological screening of natural product extracts using bioaffinity ESI-FTICR-MS as a detection means. A research plan containing three major steps has been undertaken in this study. Step one examines the current challenges in identifying protein complexes by ESI-MS and developing optimized conditions for ESI-FTICR-MS. Step two involves the development of methods for identifying complexes of targets with various molecular mass values (600 – 66,000 Da) in the setting of crude extracts. Step three uses these methods to screen natural product extracts and identify active natural product compound – protein complexes, obtaining accurate molecular mass of active compounds and their mass fingerprint. On this basis, a mass-directed purification experiment was performed to isolate the identified active compounds. The binding of the pure active compounds with the protein target was then confirmed by competition experiments with a specific inhibitor of the protein. The procedure to achieve the optimal ESI-MS condition for detecting protein - small molecule complex has been successfully developed using bCA II as the test target protein and fractional factorial design (FFD) approach. Key instrumental factors controlling the desolvation process, as well as the interactions between these factors, have been identified using FFD experiment. It has been found that flow rate, nebulizer gas pressure and drying gas flow rate are factors that greatly affect the sensi

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results